1. Home
  2. PBYI vs INSI Comparison

PBYI vs INSI Comparison

Compare PBYI & INSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBYI
  • INSI
  • Stock Information
  • Founded
  • PBYI 2010
  • INSI 1971
  • Country
  • PBYI United States
  • INSI United States
  • Employees
  • PBYI N/A
  • INSI N/A
  • Industry
  • PBYI Biotechnology: Pharmaceutical Preparations
  • INSI Investment Managers
  • Sector
  • PBYI Health Care
  • INSI Finance
  • Exchange
  • PBYI Nasdaq
  • INSI Nasdaq
  • Market Cap
  • PBYI 176.1M
  • INSI 172.0M
  • IPO Year
  • PBYI N/A
  • INSI N/A
  • Fundamental
  • Price
  • PBYI $2.30
  • INSI $16.83
  • Analyst Decision
  • PBYI Strong Buy
  • INSI
  • Analyst Count
  • PBYI 1
  • INSI 0
  • Target Price
  • PBYI $7.00
  • INSI N/A
  • AVG Volume (30 Days)
  • PBYI 393.6K
  • INSI 22.0K
  • Earning Date
  • PBYI 10-31-2024
  • INSI 01-01-0001
  • Dividend Yield
  • PBYI N/A
  • INSI 4.90%
  • EPS Growth
  • PBYI N/A
  • INSI N/A
  • EPS
  • PBYI 0.18
  • INSI N/A
  • Revenue
  • PBYI $219,143,000.00
  • INSI N/A
  • Revenue This Year
  • PBYI N/A
  • INSI N/A
  • Revenue Next Year
  • PBYI N/A
  • INSI N/A
  • P/E Ratio
  • PBYI $12.75
  • INSI N/A
  • Revenue Growth
  • PBYI N/A
  • INSI N/A
  • 52 Week Low
  • PBYI $2.13
  • INSI $14.28
  • 52 Week High
  • PBYI $7.73
  • INSI $16.40
  • Technical
  • Relative Strength Index (RSI)
  • PBYI 34.28
  • INSI 47.41
  • Support Level
  • PBYI $2.23
  • INSI $16.80
  • Resistance Level
  • PBYI $2.42
  • INSI $17.12
  • Average True Range (ATR)
  • PBYI 0.16
  • INSI 0.25
  • MACD
  • PBYI -0.00
  • INSI -0.03
  • Stochastic Oscillator
  • PBYI 12.07
  • INSI 7.23

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

About INSI Insight Select Income Fund

Insight Select Income Fund is a diversified closed-end, management investment company. The fund's investment objective is to seek a high rate of return, primarily from interest income and trading activity, from a portfolio principally consisting of debt securities. It offers various solutions such as risk management, liquidity management, and return generation among others.

Share on Social Networks: